Advertisement

Topics

$MRK FDA Grants Priority Review to sBLA for KEYTRUDA® Monotherapy for Third-Line Treatment of Patients with Advanced #SCLC. Pdufa June, 2019 https://www.businesswire.com/news/home/20190220005296/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-

06:47 EST 20 Feb 2019 | Odi Bruckman

FDA Grants Priority Review to sBLA for KEYTRUDA® Monotherapy for Third-Line Treatment of Patients with Advanced . Pdufa June, 2019 https://www.businesswire.com/news/home/20190220005296/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-Biologics …

Original Article: $MRK FDA Grants Priority Review to sBLA for KEYTRUDA® Monotherapy for Third-Line Treatment of Patients with Advanced #SCLC. Pdufa June, 2019 https://www.businesswire.com/news/home/20190220005296/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-

NEXT ARTICLE

More From BioPortfolio on "$MRK FDA Grants Priority Review to sBLA for KEYTRUDA® Monotherapy for Third-Line Treatment of Patients with Advanced #SCLC. Pdufa June, 2019 https://www.businesswire.com/news/home/20190220005296/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...